ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Impact · against what's priced in

The announcement of securities class action investigations for Disc Medicine, Qfin Holdings, and TruBridge introduces new legal liabilities. While the catalyst for Disc Medicine's investigation (the February FDA CRL) is already reflected in its price, the potential for significant settlement costs creates new downside risk across all three companies.

IRON−0.20

No priced-in read yet